Trials / Sponsors / MediQuest Therapeutics

MediQuest Therapeutics

Industry · 11 registered clinical trials.

Status	Trial	Phase	Started
Unknown	Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Raynaud Disease	Phase 3	2009-06-01
Completed	MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison Raynaud's Phenomenon	Phase 1	2009-02-01
Unknown	A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Other Autoimmune Disease	Phase 3	2007-12-01
Unknown	Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis Fingernail Psoriasis	Phase 2	2007-10-01
Completed	MQX-503 vs Nitroglycerin Ointment: A Pharmacokinetic Comparison in Normal Subjects Healthy	Phase 1	2007-08-01
Completed	Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Raynaud's Disease	Phase 2	2007-05-01
Completed	Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Raynaud's Disease, Scleroderma, Autoimmune Diseases	Phase 3	2006-12-01
Completed	Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease	Phase 2	2006-07-01
Completed	Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Raynaud's Disease	Phase 3	2005-12-01
Completed	Topical Gel Anti-Fungal Agent for Tinea Unguium Onychomycosis	Phase 2	2005-09-01
Completed	Lab Study of MQX-503 in Treatment of Raynaud's Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease	Phase 2 / Phase 3	2004-11-01